Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “AMNESIA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,693 records · Page 94Linked to original sources
PubMed1986

Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia.

In the rat, 1 min following electroshock (ECS) a 46 and 39% decrease in acetylcholine levels was found in the hippocampus and cerebral cortex, respectively. The decrease in the hippocampus was still statistically significant 30 min after ECS. The ECS applied 1 min after training also disrupted the performance of a passive avoidance conditioned response ('step down') tested 30 min later. Oxiracetam (100 and 300 mg/kg i.p.) administered 90 min before training prevented, in a dose-dependent manner, the decrease of acetylcholine in the cerebral cortex and hippocampus. Oxiracetam prevented the ECS disruption of the acquisition of a passive avoidance response. At the dose of 300 mg/kg the acetylcholine level 1 min after ECS was significantly higher than in the sham-treated rats. Piracetam at the same doses was inactive. These results support the hypothesis that oxiracetam may prevent the disruption of the conditioned response by acting on cortical and hippocampal cholinergic mechanisms.

Acetylcholine↗
PubMed1993

Stimulation of hippocampal 5-HT1A receptors causes amnesia and anxiolytic-like but not antidepressant-like effects in the rat.

Administration of 2 and 5 but not 0.4 microgram/microliter 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) into the CA1 region of the dorsal hippocampus 10 min before the acquisition trial in a passive avoidance task significantly reduced retention latencies 24 h later. The effect of 5 micrograms 8-OH-DPAT on retention latencies was completely antagonized by 1 microgram/microliter spiroxatrine, a 5-HT1A receptor antagonist, infused into the dorsal hippocampus 5 min before 8-OH-DPAT. Administered 5 min after the acquisition trial, 5 micrograms/microliters 8-OH-DPAT had no effect on retention latencies 24 h later. Administration of 5 micrograms/microliters 8-OH-DPAT into the dorsal hippocampus did not significantly change the thresholds for responses to the same electrical stimuli used in the passive avoidance task and had no antidepressant-like effect in the forced swimming test. The dose of 5 micrograms/microliters 8-OH-DPAT administered into the dorsal hippocampus caused anxiolytic-like effects assessed by stress-induced deficit in open field locomotor activity. The results suggest that stimulation of 5-HT1A receptors in the dorsal hippocampus impairs rats' performance in a passive avoidance task by interfering with memory processes or by attenuating the emotional impact of the shock through an anxiolytic action.

8-Hydroxy-2-(di-n-propylamino)tetralin↗
PubMed1996

Effects of nimodipine, felodipine and amlodipine on electroconvulsive shock-induced amnesia in the rat.

The effects of various doses (0.03, 0.1, 0.3 or 1.0 mg/kg) of the Ca2+ channel blockers nimodipine, felodipine and amlodipine on the learning ability of rats exposed to electroconvulsive shock were examined. The animals were trained in a passive avoidance procedure. The drugs tested were injected 30 min before the learning trial started. The electroconvulsive shock was given immediately after the learning trial response had been acquired. A passive avoidance retention test was performed 24 h later. It was found that electroconvulsive shock strongly impaired the retention of the passive avoidance response. Nimodipine, felodipine and amlodipine did not influence the passive avoidance behavior in the sham electroconvulsive shock group, but significantly improved the retention deficits in the animals exposed to electroconvulsive shock. These findings support the hypothesis that perturbations in Ca2+ homeostasis can contribute to the memory deficits associated with electroconvulsive shock. The antiamnestic effects of the substances tested make them interesting candidates for clinical trials in patients with cognitive impairment caused by electroconvulsive shock therapy.

Amlodipine↗